Istraživači
Bila, Jelena
| Godina | Naslov | Autor(i) | Tip rezultata | Mp-kat. |
|---|---|---|---|---|
| 2023 | Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network (✓) | Ludwig, Heinz; ...; Bila, Jelena S.   ; ...; (broj koautora 29) | Naučni članak | 21aM21a - Rad u međ. časopisu izuzetnih vrednosti |
| 2022 | MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab plus Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma | Zamagni, Elena; ...; Bila, Jelena S ; ...; (broj, koautora 22) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2022 | Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial (✓) | Terpos, Evangelos; ...; Bila, Jelena S. ; ...; (broj koautora 23) | Naučni članak | 21aM21a - Rad u međ. časopisu izuzetnih vrednosti |
| 2022 | Ocrelizumab associated late-onset neutropenia in the patient with multiple sclerosis - case report and literature review (✓) | Jovićević, Vanja; Bila, Jelena S. ; Mesaroš, Šarlota T. ; Pekmezović, Tatjana D ; Drulović, Jelena S. | Naučni članak | 23M23 - Rad u međ. časopisu |
| 2022 | Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study | Dimopoulos, Meletios A; Terpos, Evangelos; Boccadoro, Mario; Delimpasi, Sosana; Beksac, Meral; Katodritou, Eirini; Moreau, Philippe; Baldini, Luca; Symeonidis, Argiris; Bila, Jelena S ;
Oriol, Albert; Mateos, Maria-Victoria; Einsele, Hermann; Orfanidis, Ioannis; Kampfenkel, Tobias; Liu, Weiping; Kosh, Michele; NamPhuong, Tran; Carson, Robin; Sonneveld, Pieter;
| Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group (✓) | Bila, Jelena S. ; Katodritou, Eirini; Guenova, Margarita; Basic-Kinda, Sandra; Coriu, Daniel; Dapcevic, Milena; Ibricevic-Balic, Lejla; Ivanaj, Arben; Karanfilski, Oliver; Zver, Samo;
Beksac, Meral; Terpos, Evangelos; Dimopoulos, Meletios Athanassios;
| Naučni članak | 21M21 - Rad u vrhunskom međ. časopisu |
| 2021 | Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial (✓) | Dimopoulos, Meletios Athanasios; ...; Bila, Jelena S. ; ...; (broj koautora 23) | Naučni članak | 21aM21a - Rad u međ. časopisu izuzetnih vrednosti |
| 2021 | The implication and consequence of CD34+cell/subset quantity/ratio on the clinical outcome of hematologic malignancies treated by autologous stem cell transplants | Todorovic, Milena R; Pavlovic, Mirjana A; Bila, Jelena S ; Balint, Bela J | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study | Jagannath, Sundar; ...; Bila, Jelena S ; ...; (broj, koautora 45) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Ultra-high-risk prognostic significance of double and triple hit myeloma | Bila, Jelena S ; Mitrovic, Marko; Bukumiric, Zoran M ; Jovanovic, Jelica V; Dencic-Fekete, Marija; Sretenovic, Aleksandra M; Jelicic, Jelena J ; Peric, Teodora; Mihaljevic, Biljana S ; Antic, Darko A | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome (vol 105, pg 201, 2020) | Beksac, Meral; Seval, Guldane Cengiz; Kanellias, Nicholas; Coriu, Daniel; Rosinol, Laura; Ozet, Gulsum; Goranova-Marinova, Vesselina; Unal, Ali; Bila, Jelena S ; Ozsan, Hayri;
Ivanaj, Arben; Ibricevic-Balic, Lejla; Kastritis, Efstathios; Blade, Joan; Dimopoulos, Meletios Athanasios;
| Ostalo | Mp kategorija će biti prikazana naknadno. |
| 2021 | Prognostic impact of response-adjusted ISS score in Multiple Myeloma | Mitrovic, Marko; Bukumiric, Zoran M ; Sretenovic, Aleksandra M; Miketic, Ivana; Bila, Jelena S | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone +/- subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO. | Terpos, Evangelos; ...; Bila, Jelena S ; ...; (broj, koautora 20) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study | Sonneveld, Pieter; ...; Bila, Jelena S ; ...; (broj, koautora 21) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM) | Einsele, H; ...; Bila, Jelena S ; ...; (broj, koautora 23) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases (✓) | Gerhardt, Kristin; ...; Sretenović, Aleksandra M.; ...; Todorović, Milena R. ; Bila, Jelena S. ; ...; Vučinić, Vladan | Naučni članak | 21M21 - Rad u vrhunskom međ. časopisu |
| 2020 | A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome (✓) | Beksac, Meral; Seval, Guldane Cengiz; Kanellias, Nicholas; Coriu, Daniel; Rosinol, Laura; Ozet, Gulsum; Goranova-Marinova, Vesselina; Unal, Ali; Bila, Jelena S. ; Ozsan, Hayri;
Ivanaj, Arben; Ibričević-Balić, Lejla; Kastritis, Efstathios; Blade, Joan; Dimopoulos, Meletios Athanasios;
| Naučni članak | 21aM21a - Rad u međ. časopisu izuzetnih vrednosti |
| 2020 | Induction of remission in a heavily pretreated patient with diffuse large B-cell lymphoma (DLBCL) who relapsed after the therapy with CAR-T-cells - case report | Kuepper, K; Georgi, T; Bach, E; Leiblein, S; Sretenovic, Aleksandra M; Hoffmann, S; Tumewu, T; Bila, Jelena S ; Franke, G-N; Platzbecker, U;
Vucinic, Vladan;
| Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2020 | Influence of applied CD34+ cell dose on the survival of Hodgkin's lymphoma and multiple myeloma patients following autologous stem cell transplants (✓) | Todorović-Balint, Milena ; Bila, Jelena ; Balint, Bela ; Jeličić, Jelena ; Đunić, Irena ; Antić, Darko ; Kraguljac-Kurtović, Nada ; Vujić, Dragana ; Mihaljević, Biljana | Naučni članak | 23M23 - Rad u međ. časopisu |
| 2020 | Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial (✓) | Grosicki, Sebastian; ...; Bila, Jelena S. ; ...; (broj koautora 58) | Naučni članak | 21aM21a - Rad u međ. časopisu izuzetnih vrednosti |